Chart: Numbers Don't Lie: Update on Citations of False and Misleading Advertising
It's panning out to be a big year for advertising enforcement. The FDA Amendments Act infused new resources and authority into FDA's Division Drug Marketing, Advertising and Communication, allowing DDMAC to beef-up its operations and put more attention and resources into advertising enforcement ("The Pink Sheet," May 25, 2009, p. 3). Speaking at a June 22 session of the Drug Information Association annual meeting in San Diego, DDMAC Director Thomas Abrams gave an update of the division and its enforcement actions from June 2008 through May 2009.
You may also be interested in...
FDA's aggressive enforcement of its advertising standards, and the agency's new enforcement allies, mean that industry may now have more to fear from a citation letter
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials